Moleculin Biotech, Inc. (MBRX): Total Assets
$22.13M
As of 2025-12-31
$21.09M
As of 2026-06-30
-27.2%
3-year compound annual growth
-5.3%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.13M | +30.7% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $16.93M | -55.7% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $38.22M | -33.4% | 2025-03-21, Balance as of period end |
| 2022-12-31 | $57.42M | -31.7% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $84.09M | +189.7% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $29.03M | +15.0% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $25.23M | +28.8% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $19.59M | +0.5% | 2020-03-19, Balance as of period end |
| 2017-12-31 | $19.48M | +18.8% | 2019-02-21, Balance as of period end |
| 2016-12-31 | $16.39M | n/m | 2018-03-28, Balance as of period end |
| 2015-12-31 | $28.1K | n/a | 2017-04-03, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $22.13M | +30.7% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare MBRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗